Achieve Life Sciences Secures $354M Private Placement to Fund Cytisinicline Development — Achieve Life Sciences, Inc.

Event summary

Achieve Life Sciences raises up to $354M in private placement, including $180M upfront and $174M in milestone-driven warrants.
Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors, and Marshall Wace.
Proceeds to fund Phase 3 clinical trial for cytisinicline in e-cigarette cessation and commercialization efforts.
Andrew D. Goldberg, MD, appointed as new CEO effective post-closing.
Private placement expected to close on April 17, 2026.

The big picture

This $354M private placement positions Achieve Life Sciences to advance its cytisinicline program, addressing a critical gap in FDA-approved treatments for nicotine dependence and e-cigarette cessation. The influx of capital from prominent healthcare investors underscores the strategic importance of this therapeutic area, particularly as global tobacco-related deaths and vaping prevalence continue to rise. The appointment of a new CEO with deep healthcare investment experience signals a focus on commercialization and scaling the company's operations.

What we're watching

Regulatory Milestones: The pace at which the FDA approves cytisinicline will determine the exercise of $174M in warrants and the company's commercialization timeline.
Clinical Execution: Whether Achieve can successfully complete its Phase 3 trial for e-cigarette cessation will validate the use of proceeds and investor confidence.
Leadership Impact: How Andrew D. Goldberg's healthcare investment and commercial strategy expertise will influence Achieve's development and market positioning.